• Cell Biotech posted a third-quarter 2026 net loss of KRW 4.27 billion, versus a year-earlier profit of KRW 3.45 billion.
• Operating profit fell 9.4% year over year to KRW 2.01 billion.
• Revenue declined 3.3% from a year earlier to KRW 14.85 billion.
• First-nine-month operating profit rose 40.6% to KRW 6.83 billion.
• Net profit for that period dropped 18.2% to KRW 4.69 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cell Biotech Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261106900577), on November 06, 2026, and is solely responsible for the information contained therein.